IDXX vs. TAK, IQV, ALC, COR, HUM, CNC, HLN, MRNA, GEHC, and DXCM
Should you be buying IDEXX Laboratories stock or one of its competitors? The main competitors of IDEXX Laboratories include Takeda Pharmaceutical (TAK), IQVIA (IQV), Alcon (ALC), Cencora (COR), Humana (HUM), Centene (CNC), Haleon (HLN), Moderna (MRNA), GE HealthCare Technologies (GEHC), and DexCom (DXCM). These companies are all part of the "medical" sector.
Takeda Pharmaceutical (NYSE:TAK) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, community ranking, media sentiment, risk, profitability, analyst recommendations and dividends.
Takeda Pharmaceutical presently has a consensus target price of $14.00, indicating a potential upside of 5.90%. IDEXX Laboratories has a consensus target price of $580.38, indicating a potential upside of 6.79%. Given Takeda Pharmaceutical's higher possible upside, analysts clearly believe IDEXX Laboratories is more favorable than Takeda Pharmaceutical.
Takeda Pharmaceutical has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.
In the previous week, IDEXX Laboratories had 7 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 13 mentions for IDEXX Laboratories and 6 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.57 beat IDEXX Laboratories' score of 0.24 indicating that IDEXX Laboratories is being referred to more favorably in the news media.
Takeda Pharmaceutical has higher revenue and earnings than IDEXX Laboratories. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.
9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 2.1% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
IDEXX Laboratories received 426 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 72.65% of users gave IDEXX Laboratories an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.
IDEXX Laboratories has a net margin of 23.26% compared to IDEXX Laboratories' net margin of 6.18%. Takeda Pharmaceutical's return on equity of 63.66% beat IDEXX Laboratories' return on equity.
Summary
IDEXX Laboratories beats Takeda Pharmaceutical on 15 of the 17 factors compared between the two stocks.
Get IDEXX Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IDXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IDEXX Laboratories Competitors List
Related Companies and Tools
